MDRNA, Inc. to Hold Third Quarter 2009 Results Conference Call on Thursday, November 12, 2009 at 4:30 pm Eastern Time
BOTHELL, WA--(Marketwire - November 5, 2009) - MDRNA, Inc. (NASDAQ: MRNA) announced today that
it will host a conference call with investors and security analysts on
Thursday, November 12, 2009, at 4:30 pm Eastern Time (1:30 pm Pacific Time)
to provide a business update and discuss financial results for the 3rd
quarter ended September 30, 2009. To participate in the live conference
call, U.S. residents should dial 866-543-6405 and international callers
should dial 617-213-8897. The participant passcode for the live conference
call is 97970805. To access the 24-hour telephone replay, available
approximately two hours after the live event, U.S. residents should dial
888-286-8010 and international callers should dial 617-801-6888. The
participant passcode for the replay is 36119088.
Alternatively, to access the live audio webcast for this conference call
via the Internet, please go to MDRNA's website at http://www.mdrnainc.com
under Investors Event calendar or click on the following link:
http://phx.corporate-ir.net/phoenix.zhtml?c=83674&p=irol-calendar
approximately 15 minutes prior to the conference call in order to register
and download any necessary software. A replay of the webcast will be
available for 30 days following the event.
About MDRNA, Inc.
MDRNA is a biotechnology company focused on the development and
commercialization of therapeutic products based on RNA interference (RNAi).
Our goal is to improve human health through the development of RNAi-based
compounds and drug delivery technologies that together provide superior
therapeutic options for patients. Over the past decade, we have developed
substantial capabilities in molecular biology, cellular biology, lipid
chemistry, peptide chemistry, pharmacology and bioinformatics, which we are
applying to a wide range of RNAi technologies and delivery approaches.
These capabilities plus the in-licensing of key RNAi-related intellectual
property have rapidly enabled us to become a leading RNAi-based
therapeutics company with a pre-clinical pipeline in oncology. Through our
capabilities, expertise and know-how, we are incorporating multiple RNAi
technologies as well as peptide- and lipid-based delivery approaches into a
single integrated drug discovery platform that will be the engine for our
clinical pipeline as well as a versatile platform for establishing broad
therapeutic partnerships with biotechnology and pharmaceutical companies.
We are also investing in new technologies that we expect to lead to safer
and more effective RNAi-based therapeutics while aggressively building upon
our broad and extensive intellectual property estate. By combining broad
expertise in siRNA science with proven delivery platforms and a strong IP
position, MDRNA is well positioned as a leading RNAi-based drug discovery
and development company. Additional information about MDRNA, Inc. is
available at http://www.mdrnainc.com.